IBDEI1XO ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30884,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,30884,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,30885,0)
 ;;=N02.0^^123^1597^79
 ;;^UTILITY(U,$J,358.3,30885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30885,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,30885,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,30885,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,30886,0)
 ;;=N02.1^^123^1597^78
 ;;^UTILITY(U,$J,358.3,30886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30886,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,30886,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,30886,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,30887,0)
 ;;=N02.2^^123^1597^76
 ;;^UTILITY(U,$J,358.3,30887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30887,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,30887,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,30887,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,30888,0)
 ;;=N02.3^^123^1597^73
 ;;^UTILITY(U,$J,358.3,30888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30888,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30888,1,4,0)
 ;;=4^N02.3
 ;;^UTILITY(U,$J,358.3,30888,2)
 ;;=^5015514
 ;;^UTILITY(U,$J,358.3,30889,0)
 ;;=N02.4^^123^1597^72
 ;;^UTILITY(U,$J,358.3,30889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30889,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30889,1,4,0)
 ;;=4^N02.4
 ;;^UTILITY(U,$J,358.3,30889,2)
 ;;=^5015515
 ;;^UTILITY(U,$J,358.3,30890,0)
 ;;=N02.5^^123^1597^77
 ;;^UTILITY(U,$J,358.3,30890,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30890,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,30890,1,4,0)
 ;;=4^N02.5
 ;;^UTILITY(U,$J,358.3,30890,2)
 ;;=^5015516
 ;;^UTILITY(U,$J,358.3,30891,0)
 ;;=N02.6^^123^1597^74
 ;;^UTILITY(U,$J,358.3,30891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30891,1,3,0)
 ;;=3^Recurrent & perst hematur w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,30891,1,4,0)
 ;;=4^N02.6
 ;;^UTILITY(U,$J,358.3,30891,2)
 ;;=^5015517
 ;;^UTILITY(U,$J,358.3,30892,0)
 ;;=N02.7^^123^1597^75
 ;;^UTILITY(U,$J,358.3,30892,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30892,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,30892,1,4,0)
 ;;=4^N02.7
 ;;^UTILITY(U,$J,358.3,30892,2)
 ;;=^5015518
 ;;^UTILITY(U,$J,358.3,30893,0)
 ;;=N02.8^^123^1597^80
 ;;^UTILITY(U,$J,358.3,30893,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30893,1,3,0)
 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,30893,1,4,0)
 ;;=4^N02.8
 ;;^UTILITY(U,$J,358.3,30893,2)
 ;;=^5015519
 ;;^UTILITY(U,$J,358.3,30894,0)
 ;;=N02.9^^123^1597^81
 ;;^UTILITY(U,$J,358.3,30894,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30894,1,3,0)
 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,30894,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,30894,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,30895,0)
 ;;=N03.0^^123^1597^18
 ;;^UTILITY(U,$J,358.3,30895,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30895,1,3,0)
 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,30895,1,4,0)
 ;;=4^N03.0
 ;;^UTILITY(U,$J,358.3,30895,2)
 ;;=^5015521
